New cord blood treatment shows promise for tough leukemia cases
NCT ID NCT03913026
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a new way to use cord blood transplants for people with high-risk acute leukemia or myelodysplasia. The cord blood is treated with a molecule called UM171 to increase the number of stem cells, which may help the transplant work better and reduce serious side effects. The study includes 30 participants and aims to see if this approach lowers transplant-related deaths and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UM171-expanded cord blood transplant
What this could lead to
If successful, this could offer a safer and more effective stem cell transplant option for people with high-risk blood cancers, potentially improving survival and reducing transplant-related deaths.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. There are still risks of infection, graft failure, or relapse, and long-term outcomes are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIUSSS de l'Est-de-l'île-de Montreal, Hôpital Maisonneuve-Rosemont
Montreal, Quebec, H1T2M4, Canada